
    
      This is a Phase 1, randomized, double-blind, placebo-controlled, parallel group, single-dose
      study to evaluate the PK, immunogenicity, and safety of mavrilimumab at doses of 100 and 150
      mg in healthy adult Japanese subjects. The study will be conducted at one site in Europe and
      subjects will be randomized in a 5:5:2 ratio to 100, 150mg mavrilimumab and placebo.
    
  